论文部分内容阅读
本文应用异体LAK细胞联合白细胞介素2治疗慢性乙型肝炎以观察其对HBVM的转化作用。共观察66例,其中治疗组41例,对照组25例。两组治疗前、后2个月HBVM。结果发现两组的HBsAg、抗—HBs、抗—HBc均无任何改变、而治疗组抗—HBe阳转率为66.7％,HBeAg及HBcAg转阴率分别为57.1％和69.0％,与对照组比较P<0.05,差异有显著意义。而抗—HBc—IgM及HBVDNA阴转率与对照组比较P>0.05,无显著差异,可能与观察例数少或观察时间不够长有关。
In this paper, allogeneic LAK cells combined with interleukin 2 in the treatment of chronic hepatitis B in order to observe the conversion of HBVM. A total of 66 cases were observed, including 41 cases in the treatment group and 25 cases in the control group. The two groups before and after 2 months HBVM. The results showed that the HBsAg, anti-HBs and anti-HBc in both groups had no change, while the positive rate of anti-HBe in the treatment group was 66.7%, the negative conversion rates of HBeAg and HBcAg were 57.1% and 69.0% respectively, compared with the control group P <0.05, the difference was significant. The anti-HBc-IgM and HBVDNA negative conversion rate compared with the control group P> 0.05, no significant difference may be observed with fewer cases or observation time is not long enough.